AIP

aryl hydrocarbon receptor interacting protein, the group of FKBP prolyl isomerases|MicroRNA protein coding host genes

Basic information

Region (hg38): 11:67468174-67491154

Links

ENSG00000110711NCBI:9049OMIM:605555HGNC:358Uniprot:O00170AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • pituitary gigantism (Supportive), mode of inheritance: AD
  • familial isolated pituitary adenoma (Supportive), mode of inheritance: AD
  • growth hormone secreting pituitary adenoma 1 (Strong), mode of inheritance: AD

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Pituitary adenoma 1, multiple typesADEndocrine; OncologicSurveillance and/or awareness of cancer risk may allow early diagnosis of pituitary tumors (as well as related manifestations, such as hypertension, hypogonadism, diabetes mellitus, and osteoporosis), which could potentially be beneficial to allow early medical (eg, with somatostatin analogs, growth hormone receptor antagonists, dopamine agonists) or surgical treatment; Surveillance post-treatment may also be beneficial to detect recurrence/new adenomasEndocrine; Oncologic7621566; 11158006; 16728643; 17299063; 22319033; 17609395; 17244780; 17360484; 17341560; 18381572; 20570174; 20685857; 19945022; 20506337; 20507346; 21591954; 21753072; 22319033; 22720333; 22612670; 23270713; 23321498; 23674160; 23743763; 24078436
Multiple tumor types have been described

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the AIP gene.

  • not provided (24 variants)
  • Hereditary cancer-predisposing syndrome (14 variants)
  • Somatotroph adenoma (9 variants)
  • Pituitary adenoma predisposition (2 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the AIP gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
5
clinvar
243
clinvar
3
clinvar
251
missense
2
clinvar
441
clinvar
2
clinvar
1
clinvar
446
nonsense
22
clinvar
1
clinvar
23
start loss
1
clinvar
1
clinvar
2
frameshift
11
clinvar
3
clinvar
1
clinvar
15
inframe indel
1
clinvar
2
clinvar
10
clinvar
13
splice donor/acceptor (+/-2bp)
0
splice region
19
26
45
non coding
14
clinvar
68
clinvar
12
clinvar
94
Total 34 8 473 313 16

Highest pathogenic variant AF is 0.0000132

Variants in AIP

This is a list of pathogenic ClinVar variants found in the AIP region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
11-67469020-T-G not specified Uncertain significance (Sep 22, 2023)3178787
11-67469024-A-G not specified Uncertain significance (Dec 16, 2023)2407325
11-67469038-T-C not specified Likely benign (Jan 03, 2024)3178786
11-67469116-T-A not specified Uncertain significance (Jun 01, 2023)2554781
11-67469132-C-G not specified Uncertain significance (Sep 30, 2022)2314076
11-67469186-C-A not specified Uncertain significance (Aug 02, 2023)2615711
11-67481946-ATTAGTGAATTCAATTAGCCTAGTATTTTATTTAGAATGTTTCATATCAGCTGGGCGCTGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGTGGGCGGATCACGAGGTCCGGAGATTGAGACCATCCTGGCTAACACGGTGAAACCCTGTCTCTACTAAAAATACAAAAAATTAGCCGGGCATGGTGGCGGGCGCCTGTAGTCCCAGCTGCTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCAGAGCTTGCAGTGAGCTGAAATTGTGCCACTGCACTCCAGCGTGGGTGACAGAGCGAGACTCCGTCTCAAAAAAAGAAAAACAAAAGTTGTTTTAGCCCCAAAGTACCTCATTTCTCTTTTCTTTTAATTTAATTTTTTTTTTTTGTTTTGTTTTGAGACAGCATCTCGCTCTGTCGGCTAGCCTGGAGTGCAGTGGCACGAACACGGCCCACTGCAGCCTCGAACTCCTGGGCTCAAGCGATCCTCTCGCCTCGGCCTCCCAAAGTGGTGGGGTTACAGGGCCACCGCGCCCGGCGCTAAAGTACCTCATTTCTATCATTCATCGATTATTCCCTAATATTAATTGGGCACAACTATGACTCATTTCCGACCCCGCAATGGGCTCTCTTGGTCTCCTTCTCCACCTTTCTTTCCCTCTTCCTCTTTTTATTTTTTGAAAGAGGAAGATCCAGGATGCAAGAGTCCCGACAATCATACTAGATATGCGAAAGAGAAAAAGCCGGAAGAAAATACACAAAAATCATAACACTTTGAGGGTGTGGCTTACGGGTGTTTTTTTTTTTTTTCATTTTCCTAACTCTGCAGTGCTGTTATATTCCATCCACAACTTCAAACAAAGTGCCACACGGCCGCAGTCCCAATCAATTCAATGACAATTGTTAGGGACGTCCTCGTCCCGCCCGGCCCGCGGACCCCGGCCCTTCCTCCTTGACAGGCTGGGGTCCAGCCCCGAGACATTCCTAGGCTCCGCCCCCGAGCAGACGCGCGCGCTCAGCCCCAGCGCAGAGAACCAATCACCATCCGTTTCCACGCTCAGTCCCTTTTGGCTTCTGCCCTCAACCAAAATGGCGCTAGCTCGGAAGCTGCCGAGGTGCTAGGAGTTGCCGAAGCAAGTCCGGAAGCTACCGAGCGAGTCCGGAAGTTGCCGAAAGGGAGCAGCGGGGAAGGAGGATGGCGGATATCATCGCAAGACTCCGGGAGGACGGGATCCAAAAACGTGTGATACAGGAAGGCCGAGGAGAGCTCCCGGACTTTCAAGATGGGACCAAGGTTCGTGTCTACCCTACCCTTCTCCCCCTCTGCGGCGTGGTGCGCATGCGAGGCGGGAGGAGGCCTTAGGCGAGAGGTTGCGCATGCCCAGAGGGCAGCGTCCACTGCCCCTACCGCTCACATGCAGAACTCGACGCTGATTGGGCTGAATTTAAGTAGGGGGTGAATTCGGGCCTGTCTGCCCCGCCCCCTGGCTCGGCCTTGTAGCAGCATTGGTGGGGGAGGCCGTCAGTCATCACAAGCGGGTTGGGGTTGGGGGTTGATCTCAGTGCTTGGGCAGACCCCACGCTGGAGGAAACCCAGGGCCGGGAGTGGTCCTCGGGTATCTGGGTTTCAAGGCTCATGATCCTTTGTAGATGGAAGGGCCTTCTGAAAACACTTAGACCAACTGCCGCTGTTTAGAGTGGAAAACCAAGACCCTGGGACGTGCAAAGCCGGAGAACGGGCCCAGAGGTCAGGTCTCCCAGACAGGGACTCTTTAGCAGCCTTCCTGCTGCACTAGGGGCTTGTTGGGACAGATGAGGGTTGGGAAGTAAAGAACCTCCCACTTTTCTCCTTTTTGCCAGGCCCCCAGATCCAGCCCCTCTGCCCGCTTCTCCCCCAACCTACAACTCCAGGCTTCCCTGCTTCTCCTGTAGTTGCCTCCTCCCGGAGTGCTTTTCCCAGCTGCCACTTGTTTGCAGAGTAGGGAACCTCCCAGGGGCAGCCCCTGTGCCCAGCAGAGCAGTCAGGCAGGACATGCACATTGAGCAAATGAGCACATGCCCCCTGGCCAGCACCGTGCCGAATCGGGCAGCTAAGCATCCTAGCCCAGTGCAGTATAAGTGCCCTGAGAGCAGAGGGGAGCTGCATGGCTGGAGTGATCCGCTGTATGAAAAGATATCTTCTCTAAGAAGAGACAGGATGTGTGGTGTGGGTTCATGCCCCCATGTGCTGGGGGGTTGGTGGCGTTGGAAGAAGGGGCTGGCAAGGGGGATCCTGGATGGAACAGACATCAGAAGGAGAGATGTGAACAATGGCACCCCAAGATCAGAAACAGGTGGTGTTAAATAACCAATCGCCAGCACTGATTGAGTGCTCACTATTCGAACATTGTGCTACATGCTTCACACGTTTATTTCCTACAATGTGAGATAGGTACTGTTGTTGATTCCGTTTTACCGATGTGGAAACTGACTTCAGAGATGCAGCATGGTGCGGCAGTTAAGAGCGTGGGCTCCTCTAACCATATCCTGTCGAGAGTTCAATCTCCAAACCTCTTTTCTCTGCACCCACCCCCAGTGTTATCTCTAAAAACTCTCCCTGCCCGGATTACTCCCAGATGCAGCTCTCCAGTCATTAACTGTCTCTTAAACCTGATATATAGCTCCCTACTCACCATATCCACCTGGAAGCCTGGTTGGCAACTCACACTTAACCTGCTCCACCTGAGGCTTCTCCGTGTCAGGGGAACCAACAACCTTCCCGTTGTTCAGGGCAAAAACCTTAGCATCTCTGTGGTCCTCCCAGTCTCACATCCAACATCACATCCTCAATATCCAGCCAGGATCTGAGTTCTCACCACTTCTGCCATCACTGCTTGGGTCCAGGCCATCCTCATCTCCAGCCTGGGTTACTGCAGCGACCTCTAACTCTCCTGCCTCTTTTGTCCCTCTGTGGTCTGTTCTCGTCCCAGCAGCCGAGCCCATGCCAGATTCAATTCCTTTTTTGCTCGGAGCCACTCAGTGGCTTCCATCACAGAGTGAAAAACAGAGGCCTCACCATAGCCTACAGGCCCTGTGAGGTCCACCCCTACTGACCTGGGTGAGCTCCCCTGCTGACCCTGTGGTGTACCCCACCCCCTCCTTCACTCTGCTCTGCCACACTGGCATTGCTGCTCTTGAACACATCATGCATTTGAAACGGGAAGTTCCCTTGTCTCCCTCGCAGGGCGTGCGATGGGGGAGTGGCTCGCTTCTTCAGTGCCCCGCTGCTCAGACCTCTGGGGGAGCATACAGATGGGCAGGCTGTGGGCTCCGACCTCATGGCAGTGTCTAGGGGTGAATATTTACAGCTCCGTGTGTTCTAGGGTGCTCTTTTAGTTTGTCTATGGGAGGCTTGTGTTAACCAGCTCAATTAGACCCCCTTCCTTATCACAAGGACAGAGGGCTTTCTGTAGTCTGGGGTTTTCTTGCCTTGATGTACTGGAGTACTGGAGAATTAGATCACTTGTGGGCTTGGAGAATGATTGCAAATTTTTTTTTATTTTTTATTTTATTTTTTTTTTCTGAGATGGAGTTTCACTCTTGTTGCCCAGGCTGGAGTGCAATGGCACAATCTCTGCCTCCCAGGTTCAAGCAATTCTCCTGCCTCAGCCTCCCAAGTAGCTGAGATTACATGTGCCTGACACCAGGCCCGGCTAATTTTTAAAAATGTTTTTAGTAGAGATGGGCTTTTACCATGTTGGCCAAGCTGGTTTCAAACGCCTTTTTTTTTTTTTTTTTTTTTGAGACGGAGTCTTGCTCTATTGCCCAAGCTGGAGTGCAGTGGCATGATCTCGGTTCACTGCAACCTCCACCTTCTGGGTTCAAGTGATTCTCCTGCCTCAGCCTCCCAAGTAGCTGGGATTACAGGCACCCGCCATCATGGCCAGCTAATTTTTGTATTTTTAGTAGAGACGGGGTTTTGCCACATTGGCCAGGCTGGTCTTGAACTCCTGACCTCAGGTGATCCACCCGCCTTGGAGATGGTCTTCCCCTGGGGTTGGGCCACTTGGTGGCCCCACCTCTCCTCTGACTGCCCCAGCCAAACTCCGCCTCTTCCTGCCAGTTGATGACCTGCCAGCGTGCAGGTGCCTGTCAGTGTGATCTTCTGCTTCTTGCTCCCCTGACATCCTCTCAATGACCAGGAGCTCGTCTTCTGCTGATGGGCTCCTCTGACATCTGGCTGCCTGTGGGTCTACCCCCTAGGGGTGTTGGGTTTTTATAGGCACAGGATAGGGGTGTGGCAGGCCAGGGTGGTCTTGGGAAATGCAACATTTGGGCAGGAAATGCCTGTTCTCACCTAGGTCTGTGGGGGTGGAACCCTACCCAGGGACCACGCCCTCCTCTACCCAGCACTTCCCTTCTCCCCTTCCAAATTATTTAACAGGACCATGCTCCTCCCTTCCCAGCACTTCCATATCACATTGTCCCACTGCAAGGCTTTTTTACACATGCTGTTCTTTTGGCCTAGAAAGTTCCTATCCCAGGGTCCACTTGGCTTGCTTTCTTCCTTACTCCCCAACCCCCCACTCTGTTTAATCCAGCCCCAACCCTCTTGCCCTGCTGTTTCCCAAGCACGTGGCTTCACCTGCCATGACATATTGTTTTGTTTGATGCCCATCTCCTCCCTCTAGAAGCGCCATGTGAGCTCCAGGGGGGCAGGGACTTTTTTGTGTTTTGCTTGCTGCCATGTTCTGGTGTCTAGCACAGAGCTTGGGCACATAGTAGGTGCTTAGTAAATATCTGTTGAGGAATGACTGGAGTCAGACTGCTTGGACTCTTGTTCCCACTCAGCCACCCACTAGCCGTGTGGCTTGGGCCTATTCCTCCCCTCCTTGTGGCTTTGTTTTCTCACCAGCGTGGGAGGATGAAGCCAGGTGTAAGGTCAGGTGGTGTCCCCGGGGAAGCCCCGTCCCTTATGCCGTCTGCAGGCCGGGGACTGGACTTCTCCTTGGGGGTCAGGGTGAGGGTTTGTGCCTTTGCCTGACCTCGCATGTGGCCCACAGGCCACGTTCCACTACCGGACGCTGCACAGTGACGACGAGGGCACCGTGCTGGACGACAGCCGGGCTCGTGGCAAGCCCATGGAGCTCATCATTGGCAAGAAGTTCAAGCTGCCTGTGTGGGAGACCATCGTGTGCACCATGCGAGAAGGGGAGATTGCCCAGTTCCTCTGTGACATCAAGGTGTCTGTCCTGTACCTGTCTGCGGTGGCTGTCCAGCCAAGCCCTATTCCTATTCCCTATCCCCAGGGCTCCTCCTCCCTCCACCCTCTGCTAGACTGCCACCCGCTTTCTTTTTTTTTTTGAGATGGAGTCTTGCTCTGTCGCCCAGGCTGGAGTGCAGTGGTACGATCTCAGCTCACTGCACCCTCCACCTCCTGGGTTCAAGCGATTCTTCTGCCTCAGCCTCCCGAGTAGCTGGGATTACAAACACCCGCCATGATGCCTGGCTAATTTTTGTATTTTTAGTAGAGACAGGGTTTCACCATGTTGGCCAGGCTGGTCTTGAACACCTGACCTCAGGTGATCCACCCGCCTTGGCCTCCCAAAGTGCTGGGATTATAGGCGTGTGCCACCGCGCCCGGCCCACCCACTCTTTCCAGACCACCACACCAGCCTGCTGATGGCGTCCTGGCCTCCATTCCGCCTTCCCCTATTAGCCAGACTGAGGCCAGGGGACTCGTTCTCAAATGCAAATGACCTGTACATCCCTTTGTTTCAAACCTCTATGACTCCTGGTCACTGTAAGGATAGAGCACAGG-A Somatotroph adenoma Likely pathogenic (Jun 21, 2012)41158
11-67482759-G-GT Benign (Aug 19, 2019)1234779
11-67482889-CG-AA Uncertain significance (Jan 24, 2024)424703
11-67482890-G-C Uncertain significance (Jan 12, 2024)2710182
11-67482897-G-C Likely benign (Oct 01, 2023)2642021
11-67482939-G-A - no classification for the single variant (-)242676
11-67483074-C-T Somatotroph adenoma Uncertain significance (Jan 13, 2018)879697
11-67483075-C-G Somatotroph adenoma Benign (Jan 13, 2018)305719
11-67483136-A-G Somatotroph adenoma Benign (Jan 13, 2018)305720
11-67483147-C-G Somatotroph adenoma Uncertain significance (Jan 13, 2018)305721
11-67483154-G-A AIP-related disorder • Hereditary cancer-predisposing syndrome Uncertain significance (Mar 27, 2024)3051739
11-67483154-G-C Somatotroph adenoma not provided (-)41159
11-67483156-A-G Hereditary cancer-predisposing syndrome Uncertain significance (Jun 03, 2022)824477
11-67483157-G-A Hereditary cancer-predisposing syndrome Uncertain significance (Jun 13, 2022)1798666
11-67483157-G-C Somatotroph adenoma Uncertain significance (Jan 13, 2018)305722
11-67483160-T-C Somatotroph adenoma Uncertain significance (Feb 24, 2023)41173
11-67483161-G-A Familial isolated pituitary adenoma Likely pathogenic (Aug 19, 2016)253315
11-67483161-G-GC Somatotroph adenoma not provided (-)41177
11-67483162-G-C Hereditary cancer-predisposing syndrome Uncertain significance (Nov 01, 2023)825361

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
AIPprotein_codingprotein_codingENST00000279146 68063
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.3620.6381257100121257220.0000477
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense0.9301732110.8200.00001402159
Missense in Polyphen5383.810.63238916
Synonymous-0.1739289.91.020.00000631643
Loss of Function3.01417.70.2269.38e-7174

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.00002910.0000291
Ashkenazi Jewish0.000.00
East Asian0.000.00
Finnish0.0003230.000323
European (Non-Finnish)0.00003590.0000352
Middle Eastern0.000.00
South Asian0.000.00
Other0.000.00

dbNSFP

Source: dbNSFP

Function
FUNCTION: May play a positive role in AHR-mediated (aromatic hydrocarbon receptor) signaling, possibly by influencing its receptivity for ligand and/or its nuclear targeting.;
Disease
DISEASE: Prolactin-secreting pituitary adenoma (PSPA) [MIM:600634]: Most common type of hormonally active pituitary adenoma. {ECO:0000269|PubMed:16728643, ECO:0000305|PubMed:17244780}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Pathway
Cushing,s syndrome - Homo sapiens (human);Aryl Hydrocarbon Receptor;Aryl Hydrocarbon Receptor Pathway;Nuclear Receptors Meta-Pathway;Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation;ahr signal transduction pathway;Aryl hydrocarbon receptor signalling;Phase I - Functionalization of compounds;Biological oxidations;Metabolism (Consensus)

Recessive Scores

pRec
0.133

Intolerance Scores

loftool
0.171
rvis_EVS
-0.14
rvis_percentile_EVS
43.77

Haploinsufficiency Scores

pHI
0.511
hipred
Y
hipred_score
0.793
ghis
0.522

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.960

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Aip
Phenotype
cellular phenotype; homeostasis/metabolism phenotype; endocrine/exocrine gland phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); growth/size/body region phenotype; embryo phenotype; neoplasm; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); liver/biliary system phenotype;

Gene ontology

Biological process
protein targeting to mitochondrion;xenobiotic metabolic process;regulation of protein kinase A signaling;protein maturation by protein folding;interleukin-12-mediated signaling pathway;negative regulation of cyclic-nucleotide phosphodiesterase activity;positive regulation of nucleic acid-templated transcription
Cellular component
nucleoplasm;cytoplasm;cytosol;plasma membrane;aryl hydrocarbon receptor complex
Molecular function
transcription coactivator activity;protein binding;transcription factor binding;aryl hydrocarbon receptor binding;GAF domain binding;unfolded protein binding